IBDEI09J ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4028,2)
 ;;=Lt Effect of Stroke w/Vision prob^328504
 ;;^UTILITY(U,$J,358.3,4029,0)
 ;;=250.50^^14^184^5
 ;;^UTILITY(U,$J,358.3,4029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4029,1,3,0)
 ;;=3^250.50
 ;;^UTILITY(U,$J,358.3,4029,1,4,0)
 ;;=4^Diabetes II w/ OPHTH manifestations
 ;;^UTILITY(U,$J,358.3,4029,2)
 ;;=Diabetes w/ OPHTH manifestations^267839
 ;;^UTILITY(U,$J,358.3,4030,0)
 ;;=363.20^^14^184^3
 ;;^UTILITY(U,$J,358.3,4030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4030,1,3,0)
 ;;=3^363.20
 ;;^UTILITY(U,$J,358.3,4030,1,4,0)
 ;;=4^Chorioretinitis, Unspecified
 ;;^UTILITY(U,$J,358.3,4030,2)
 ;;=^23913
 ;;^UTILITY(U,$J,358.3,4031,0)
 ;;=365.9^^14^184^6
 ;;^UTILITY(U,$J,358.3,4031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4031,1,3,0)
 ;;=3^365.9
 ;;^UTILITY(U,$J,358.3,4031,1,4,0)
 ;;=4^Glaucoma, Unspecified
 ;;^UTILITY(U,$J,358.3,4031,2)
 ;;=Glaucoma, Unspecified^51160
 ;;^UTILITY(U,$J,358.3,4032,0)
 ;;=115.90^^14^184^7
 ;;^UTILITY(U,$J,358.3,4032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4032,1,3,0)
 ;;=3^115.90
 ;;^UTILITY(U,$J,358.3,4032,1,4,0)
 ;;=4^Histoplasmosis, NOS w/o Manifestation 
 ;;^UTILITY(U,$J,358.3,4032,2)
 ;;=^57700
 ;;^UTILITY(U,$J,358.3,4033,0)
 ;;=362.9^^14^184^16
 ;;^UTILITY(U,$J,358.3,4033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4033,1,3,0)
 ;;=3^362.9
 ;;^UTILITY(U,$J,358.3,4033,1,4,0)
 ;;=4^Retinal Disorder
 ;;^UTILITY(U,$J,358.3,4033,2)
 ;;=^105548
 ;;^UTILITY(U,$J,358.3,4034,0)
 ;;=362.75^^14^184^18
 ;;^UTILITY(U,$J,358.3,4034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4034,1,3,0)
 ;;=3^362.75
 ;;^UTILITY(U,$J,358.3,4034,1,4,0)
 ;;=4^Stargardts
 ;;^UTILITY(U,$J,358.3,4034,2)
 ;;=^268656
 ;;^UTILITY(U,$J,358.3,4035,0)
 ;;=E929.9^^14^184^8
 ;;^UTILITY(U,$J,358.3,4035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4035,1,3,0)
 ;;=3^E929.9
 ;;^UTILITY(U,$J,358.3,4035,1,4,0)
 ;;=4^Late Eff Accident NOS
 ;;^UTILITY(U,$J,358.3,4035,2)
 ;;=^294770
 ;;^UTILITY(U,$J,358.3,4036,0)
 ;;=V43.1^^14^184^9
 ;;^UTILITY(U,$J,358.3,4036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4036,1,3,0)
 ;;=3^V43.1
 ;;^UTILITY(U,$J,358.3,4036,1,4,0)
 ;;=4^Lens Replacement NEC
 ;;^UTILITY(U,$J,358.3,4036,2)
 ;;=^69114
 ;;^UTILITY(U,$J,358.3,4037,0)
 ;;=369.4^^14^185^37
 ;;^UTILITY(U,$J,358.3,4037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4037,1,3,0)
 ;;=3^369.4
 ;;^UTILITY(U,$J,358.3,4037,1,4,0)
 ;;=4^Legal Blindness (USA definition)
 ;;^UTILITY(U,$J,358.3,4037,2)
 ;;=^268887
 ;;^UTILITY(U,$J,358.3,4038,0)
 ;;=369.01^^14^185^24
 ;;^UTILITY(U,$J,358.3,4038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4038,1,3,0)
 ;;=3^369.01
 ;;^UTILITY(U,$J,358.3,4038,1,4,0)
 ;;=4^BE:NLP; LE:NLP
 ;;^UTILITY(U,$J,358.3,4038,2)
 ;;=Totally Blind, NLP or LPO^268861
 ;;^UTILITY(U,$J,358.3,4039,0)
 ;;=369.02^^14^185^21
 ;;^UTILITY(U,$J,358.3,4039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4039,1,3,0)
 ;;=3^369.02
 ;;^UTILITY(U,$J,358.3,4039,1,4,0)
 ;;=4^BE:CF,HM,LP,VF<5;LE:NOS
 ;;^UTILITY(U,$J,358.3,4039,2)
 ;;=^268862
 ;;^UTILITY(U,$J,358.3,4040,0)
 ;;=369.05^^14^185^17
 ;;^UTILITY(U,$J,358.3,4040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4040,1,3,0)
 ;;=3^369.05
 ;;^UTILITY(U,$J,358.3,4040,1,4,0)
 ;;=4^BE:<10 or 20/500-20/1000;LE:Not Specified
 ;;^UTILITY(U,$J,358.3,4040,2)
 ;;=^268865
 ;;^UTILITY(U,$J,358.3,4041,0)
 ;;=369.11^^14^185^18
 ;;^UTILITY(U,$J,358.3,4041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4041,1,3,0)
 ;;=3^369.11
 ;;^UTILITY(U,$J,358.3,4041,1,4,0)
 ;;=4^BE:<20 or 20/200-20/400;LE:Not Specified
 ;;^UTILITY(U,$J,358.3,4041,2)
 ;;=^268871
 ;;^UTILITY(U,$J,358.3,4042,0)
 ;;=369.16^^14^185^15
